BioSpace News Archive

C4 Therapeutics, Inc. announced the appointment of Kendra Adams as chief financial officer, effective September 18, 2023.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference.

Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.

Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company’s senior management team will participate in the following investor conferences in September.

bluebird bio, Inc. announced that members of the management team will participate in fireside chats at the following upcoming investor conferences.